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Unadjusted engraftment rates were higher and median time to
engraftment was earlier for NW than W PD CB: 91  4% and 20
days for NW vs 88  4% and 24 days for W for ANC 500 (P 
0.03), 86  6% and 44 days for NW vs 78  5% and 58 days for
W for platelet 20,000 (P  0.004), 85  6% and 57 days for NW
vs 72 6% and 75 days for W for platelet 50,000 (P 0.01). Acute
grade III-IV GvHD incidence was 12% (NW) and 13% (W), and
extensive chronic GvHD was 4% (NW) and 19% (W). Relapse
rates were 16  5% for NW and 28  5% for W (P  0.15), with
TRM for at 25  5% for NW and 34  5% for W (P  0.52).
One-year OS was 63 6% vs 49 5% (P 0.40), and 1-year DFS
was 62  6% vs 36  7% for NW and W (P  0.21), respectively.
Outcome for PD CBT compare favorably to published data of
outcomes using RBC depleted CBT and trended better with re-
spect to engraftment, TRM and survival. There appears to be no
clear beneﬁt for post-thaw washing of PD CB, and not washing
may be better than post-thaw washing of PD CB with respect to
neutrophil and platelet engraftment rate and speed to engraftment,
TRM, relapse rate, 1-year OS and DFS.
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COMPARISON OF CORD BLOOD PRODUCT THAWING METHODS ON
CELL RECOVERY AND PROGENITOR INTEGRITY
Regan, D.M.,1 Grunzinger Nelms, L.M.,1 Wofford, J.D.,1
Alonso, J.F. III,1 Creer, M.H.2 1St. Louis Cord Blood Bank @ SSM
Cardinal Glennon Children’s Hospital, St. Louis, MO; 2St. Louis Uni-
versity Health Sciences Center, St. Louis, MO.
Umbilical cord blood (UCB) products have traditionally been
thawed using a conventional washing (CW) method intended to
stabilize the cells, reduce DMSO toxicity and remove potentially
ABO-incompatible RBC stroma and plasma. Concerns with CW
include total nucleated cell (TNC) loss, bag breakage during cen-
trifugation and poor reproducibility by transplant centers unfamil-
iar with this technique. We compared CW, albumin reconstitution
without centrifugation (AR), and direct thaw (DT, no dilution or
wash) methods by assessing viability and TNC, CD34 and colony-
forming cell (CFC) recovery post-thaw. Ten cryopreserved UCB
products were thawed, split equally into three parts, processed by
CW, AR and DT methods and post-thaw tests performed at
multiple time intervals up to 48 hours. Mean TNC recovery by
CW was lower than DT (P  0.01) throughout the 48 hour
interval, however, CW and AR recoveries were not different (P 
0.05). CD34 and CFC in CW, AR and DT did not differ up to 2
hours but CFC recovery in DT progressively declined with no
CFC recovered at 32 hours. In DT, CD34 recovery declined
progressively after eight hours compared to AR and CW (P 
0.0009). Throughout the entire evaluation, CW and AR methods
performed equally well with no signiﬁcant differences observed in
viability, TNC, CD34 or CFC recovery. Subsequent to the success
of this study, AR has been used for 6 patients with no apparent
effect on engraftment compared to CW.
We conclude that removing DMSO, RBC stroma and plasma post
thaw using CW is not necessary when CB products are RBC and
plasma depleted before cryopreservation and have implemented the
practice of reconstituting units in our laboratory where environmental
conditions are controlled and the infused product characterized. Re-
constituting products is safe, easily standardized and comparable to
conventional wash in maintaining cellular and progenitor integrity
while ensuring recipient safety during infusion.
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GRAFT-VERSUS-LEUKEMIA EFFECT AFTER ALLOGENEIC TRANSPLAN-
TATION FOR ACUTE LEUKEMIA
Eapen, Mary. Center for International Blood and Marrow Transplant
Research (CIBMTR), Milwaukee, WI.
It is widely accepted that donor lymphocytes can eradicate tumor
cells that survive preparative regimens and the occurrence of
chronic graft-versus-host disease (GVHD) associated with fewer
relapses. This lower risk does not always translate into a survival
advantage, as chronic GVHD is associated with higher transplant-
related mortality (TRM).
We examined the inﬂuence of GVHD on relapse and mortality in
an era where peripheral blood grafts are increasing used for allogeneic
transplantation. We performed a retrospective analysis of 1754 recip-
ients of HLA-matched sibling donor transplants in 1996-2003 for
acute lymphoblastic (ALL) or acute myeloid (AML) leukemia. Com-
pared to patients with ALL, those with AML were older, more likely
to be in 1st clinical remission and receive a non-total body irradiation
containing regimen. All patients received non-manipulated grafts and
approximately 50% received peripheral blood grafts.
After adjusting for other signiﬁcant factors, relapse rates were sim-
ilar in those with and without acute GVHD. The inﬂuence of chronic
GVHD on relapse, TRM and overall mortality varied by type of
leukemia. Chronic GVHD was associated with lower relapse rates in
ALL (RR 0.83, P  0.013) but relapse rates were not statistically
different in AML (RR 0.96, P  0.496). Among patients with AML,
TRM was higher in those with both acute (RR 1.45, P  0.005) and
chronic (RR 1.65, P 0.003) GVHD, a trend not seen amongst those
with ALL. While overall mortality rates did not differ signiﬁcantly in
patients with and without acute GVHD, rates were signiﬁcantly lower
in patients with ALL who developed chronic GVHD (RR 0.80, P 
0.001). This survival advantage contrasts most reports and requires
conﬁrmation in a larger data set. Though GVHD rates were higher
after transplantation of peripheral blood relative to bone marrow, the
inﬂuence of GVHD on relapse and mortality did not differ by graft
type suggesting that there may be a GVHD threshold beyond which
there is no additional beneﬁt with respect to either recurrence or
survival.
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NK CELLS AND KIR MISMATCH IN CORD BLOOD TRANSPLANTATION
Miller, Jeffrey S., Brunstein, Claudio G., McKenna, David H.,
Wagner, John E. Blood and Marrow Transplant Program, University of
Minnesota, Minneapolis, MN.
We have shown that NK cell killer Ig-like receptor (KIR) interac-
tions predict better survival in recipients of adult donor unrelated
transplant. We studied KIR reconstitution from recipients at day
100 after transplant from different allogeneic cell sources. Adult
marrow unrelated donor grafts resulted in signiﬁcantly lower KIR
recovery than from UCB sources (27.31 2.06%, n 36 vs 37.99
2.54%, n  49, P  .0027), which may have clinical consequences.
We have recently found that NK cell receptor expression deﬁnes
maturation on developing NK cells and hypothesized that NK cell
alloreactivity would predict oucomes in recipients of UCBT. We
therefore assessed the effect of KIR-L MM in 243 recipients of UCB
transplanted at the University of Minnesota. KIR-L MM in the GVH
direction was found in 70 (29%) donor-recipient pairs.
Using this strategy, there was no difference in 2-year survival, or
GVHD. In contrast, relapse was less in recipients of single UCB
transplants who were KIR-L MM but for the entire group, the
incidence of TRM was higher among recipients of KIR-L MM grafts
[26% vs 13%, P  0.01] complicating detection of any possible
beneﬁt. Although we fail to support a speciﬁc search for UCB units
with a KIR-L MM, we are exploring methods to better activate NK
cells in vivo to optimize NK cell effects to decrease relapse after UCB
transplant. Based on our experience using haploidentical NK cells
from adult donors, we ﬁnd that anti-tumor activity in AML patients
corresponds with the in vivo expansion of NK cells stimulated by a
surge in endogenous IL-15 but NK cells. In an attempt to improve on
these outcomes, NK cell precursors from a third UCB unit are being
expanded in vivo after a myeloablative conditioning to test the NK cell
therapy potential of UCB in patients with poor prognosis AML.
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DIFFERENTIATION OF NAIVE CORD BLOOD T CELLS INTO CD19-SPE-
CIFIC CYTOLYTIC EFFECTORS FOR POST-TRANSPLANTATION ADOP-
TIVE IMMUNOTHERAPY
Cooper, Laurence J.N. MD Anderson Cancer Center, Houston, TX.
Disease relapse is a barrier to achieving therapeutic success after
unrelated umbilical cord blood transplantation (UCBT) for
B-lineage acute lymphoblastic leukemia (B-ALL). While adoptive
transfer of donor-derived tumor-speciﬁc T cells is a conceptually
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